QDEL · QuidelOrtho Corporation

Current Thesis

QuidelOrtho is a post-COVID legacy diagnostics name in a confirmed downtrend, not a momentum setup. The Q1 2026 print (May 5) put revenue at $619.8M, down 10.5% YoY and ~$45M below the $665M consensus, with adjusted EPS of ($0.04) versus +$0.37 expected. Management cut FY2026 guidance the same week, and Jefferies, JPMorgan and UBS all slashed price targets into the $11–$12.50 range. Price sits near the bottom of its 52-week range ($9.92–$35.58), below every major moving average. This is the cheap-multiple-rolled-over-structure profile the playbook flags as a value trap no accelerating narrative to buy, no fresh catalyst, no base. DORMANT until it proves a higher low.

Bull Case

• Trough valuation, recurring razor-blade model. Market cap ~$977M (Jun 5) on a $2.70–$2.75B FY2026 revenue guide ≈ 0.36x sales; FY2026 adj. EBITDA guide $615–630M. Vitros/Savanna installed-base consumables are sticky, recurring revenue the franchise is not melting, the comps are.
• Headwinds framed as cyclical, not structural. On the Q1 call (May 5) management attributed the miss to a weak respiratory season, China distributor destocking on proposed NHSA reimbursement cuts, and EMEA order delays from geopolitical conflict all potentially transient. A normal respiratory season alone reverses a chunk of the YoY decline.
• Still FCF-positive. FY2026 free-cash-flow guide $100–120M despite the cut the business funds itself, leaving optionality for debt paydown.
• Sentiment washed out. Three PT cuts already absorbed; consensus is uniformly "Hold," not "Buy." A single in-line-to-better Q2 print (est. ~early Aug) could force a short-covering mean-reversion off the 52-week low.

Bear Case

• Guidance cut, twice-trimmed trajectory. FY2026 revenue guide lowered to $2.70–2.75B from $2.7–2.9B; adj. EBITDA to $615–630M from $630–670M; adj. EPS to $1.80–2.00 from $2.00–2.42 (all May 5). Estimates are still falling, not basing.
• Margin compression is the real tell. Q1 adj. EBITDA margin collapsed to 17.5% from 23.1% YoY; GAAP operating loss of $32M and net loss of $92M.
• China NHSA reimbursement risk is structural, not weather. Proposed reimbursement cuts threaten the entire China distributor channel a multi-quarter overhang, not a one-print event.
• Levered balance sheet from the Ortho deal. The 2022 Ortho Clinical acquisition loaded the balance sheet; the Q3 2025 non-cash goodwill impairment of $701M is the admission the deal was overpaid. TTM GAAP EPS of ~-$17.81 reflects that write-down. Only $100–120M FCF against that debt load leaves thin margin for error.
• Downtrend intact. ~60% below the 52-week high; no reversal structure.

Setup & Price Structure

• Last ~$14.33 (Jun 5 close), -6.34% on the day. 52-week range $9.92–$35.58 price sits in the bottom ~15% of the range, ~44% above the absolute low and ~60% off the high.
• Structure is a clean downtrend: price below a declining 20-week EMA, lower highs since the $35 area, gap-down and follow-through after the May 5 print. No higher low yet, no base.
• This is a falling-knife profile, not an oversold-bounce-with-confirmation. RSI is depressed but depressed-RSI in a downtrend is continuation, not a buy signal. There is no momentum leg to ride here strength is absent, which in this playbook means there is no setup.

Catalyst Calendar (next 30 days)

• No binary catalyst inside the 30-day window.
• 2026-06-02 William Blair 46th Annual Growth Stock Conference presentation (already passed; not a needle-mover).
• 2026-06-03 Jefferies Global Healthcare Conference fireside chat (already passed).
• Q2 2026 earnings est. ~2026-08-04 (outside the 30-day window; Q1 printed May 5). This is the next real binary.
• No FDA/PDUFA dates or product launches dated within 30 days.

What Would Change Our Mind

• A weekly higher low forming above the $9.92 52-week low, then a reclaim of the declining 20-week EMA on expanding volume the first technical evidence the downtrend is breaking.
• A Q2 2026 print (~early Aug) that stabilizes or raises the cut guide and shows respiratory/China revenue inflecting back toward YoY-flat.
• Concrete resolution of the China NHSA reimbursement overhang (final rule less severe than feared).
• Relative strength versus diagnostics peers (DHR, RVTY, A) QDEL leading the group up rather than lagging it down would flip the theme read from value-trap to early turnaround.

Correlation Notes

• Diagnostics / life-science-tools cohort: Danaher (DHR/Cepheid), Revvity (RVTY), Agilent (A), Thermo Fisher (TMO), Abbott diagnostics (ABT), Bio-Rad (BIO). QDEL trades as the low-quality, high-beta, levered name in this group it underperforms on the way down and is the last to be bought on the way up.
• Shared China NHSA reimbursement risk: any diagnostics name with China distributor exposure moves on the same regulatory headlines.
• Respiratory-season beta: correlated with Abbott and Cepheid respiratory franchises; a strong flu/COVID season lifts the cohort together.
• Macro: small-cap, levered medtech sensitive to risk-off and rate moves more than its mega-cap peers; thin liquidity amplifies both directions.